AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus®[1] in persistence to treatment - Seite 2
"These results fully validate our decision at Sandoz to develop our inhaler device in close collaboration with patients, incorporating their feedback", said Dr. Spencer Jones, Sandoz Head of Global Medical Affairs, Respiratory. "This approach, which results in the device being effectively designed to give direct feedback to users, is the key to success in treating chronic conditions."
He added: "What the data also highlight is the need for even more research to better understand patient persistence behaviors and to develop strategies to address what are still unacceptably low overall levels."
The study was designed to retrospectively analyze persistence rates between the two devices, using dispensing data from a large German pharmacy database. While retrospective database analyses have some limitations, the strengths of this data include the fact that 11,744 patients were included in a matched pair analysis, controlled for gender, age and month of treatment initiation (to limit seasonal effects).
All patients were first time users of salmeterol/fluticasone propionate and persistence to treat was analyzed for a 12 month period.
About AirFluSal Forspiro
AirFluSal Forspiro offers the proven combination of salmeterol (a long-acting inhaled ß2-agonist) and fluticasone propionate (an inhaled corticosteroid) in an innovative device. Safety, efficacy
and equivalence have been proven in multiple clinical trials.
It was developed at Aeropharm GmbH in Rudolstadt, Germany, Sandoz's global respiratory Center of Excellence. Sandoz collaborated with UK-based Vectura Group plc, a respiratory product development company, in the design and development of the product. The innovative and intuitive-to-use inhaler was invented at Vectura and its design was awarded the Red Dot Product Design award in 2011, an internationally recognized quality seal awarded by the Design Zentrum Nordrhein Westfalen in Essen, Germany.
In order to improve patient experience with inhalation devices, Sandoz and Vectura collaborated closely with patients during the development process. The device includes multiple feedback mechanisms such as visual control features, which help reassure the patient about dosing and a simple lever arm to load the dose.
Lesen Sie auch
AirFluSal Forspiro has been launched to date in approximately 30 countries, in Europe and elsewhere.
Disclaimer
This press release contains forward-looking statements that can be identified by terminology such as "long-term," "persistent," "growing," "suggests," "may," "likely," "strategies," or similar
terms, or by express or implied discussions regarding potential additional marketing approvals for AirFluSal Forspiro, or regarding potential future revenues from AirFluSal Forspiro. You should not
place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant
known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from
those set forth in the forward-looking statements. There can be no guarantee that AirFluSal Forspiro will be submitted or approved for any additional indications or labeling in any market, or at
any particular time. Nor can there be any guarantee that AirFluSal Forspiro will be commercially successful in the future. In particular, management's expectations regarding AirFluSal Forspiro
could be affected by, among other things, the uncertainties inherent in research and development, including unexpected regulatory actions or delays or government regulation generally; unexpected
clinical trial results and additional analysis of existing clinical data; the company's ability to obtain or maintain proprietary intellectual property protection; general economic and industry
conditions; global trends toward health care cost containment, including ongoing pricing pressures; unexpected safety, quality or manufacturing issues, and other risks and factors referred to in
Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any
obligation to update any forward-looking statements as a result of new information, future events or otherwise.